Matthew B Lanktree Selected Research

Temtamy preaxial brachydactyly syndrome

12/2010

Temtamy preaxial brachydactyly syndrome is caused by loss-of-function mutations in chondroitin synthase 1, a potential target of BMP signaling.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Matthew B Lanktree Research Topics

Disease

8	Autosomal Dominant Polycystic Kidney (ADPKD) 01/2021 - 12/2017
5	Cardiovascular Diseases (Cardiovascular Disease) 07/2022 - 04/2009
2	Metabolic Syndrome (Dysmetabolic Syndrome X) 07/2022 - 01/2013
2	Cysts 01/2021 - 12/2017
2	Kidney Diseases (Kidney Disease) 01/2021 - 01/2018
2	Hemochromatosis (Bronze Diabetes) 03/2017 - 01/2015
2	Iron Overload 03/2017 - 01/2015
1	Non-alcoholic Fatty Liver Disease 07/2022
1	Bone Diseases (Bone Disease) 01/2022
1	COVID-19 01/2021
1	Polycystic Kidney Diseases (Polycystic Kidney Disease) 11/2019
1	Tuberous Sclerosis (Bourneville's Disease) 11/2019
1	Cystic Kidney Diseases (Cystic Kidney Disease) 01/2019
1	Polycystic liver disease 10/2018
1	Albuminuria 01/2018
1	Chronic Kidney Failure (Chronic Renal Failure) 01/2018
1	Vascular Diseases (Vascular Disease) 01/2018
1	Chronic Renal Insufficiency 01/2018
1	Neuroferritinopathy 03/2017
1	Coronary Disease (Coronary Heart Disease) 03/2015
1	Hyperferritinemia 01/2015
1	Insulin Resistance 01/2013
1	Stroke (Strokes) 07/2012
1	Neoplasms (Cancer) 07/2012
1	Myocardial Infarction 07/2012
1	Hypertriglyceridemia 08/2011
1	Temtamy preaxial brachydactyly syndrome 12/2010
1	Deafness (Deaf Mutism) 12/2010
1	Brachydactyly 12/2010
1	Thrombosis (Thrombus) 09/2010
1	Atherosclerosis 09/2010
1	Triple X syndrome 08/2009
1	Lipodystrophy 08/2009
1	Coronary Artery Disease (Coronary Atherosclerosis) 02/2009
1	Type 2 Diabetes Mellitus (MODY) 02/2009

Drug/Important Bio-Agent (IBA)

4	Proteins (Proteins, Gene)FDA Link 01/2021 - 07/2012
4	LipidsIBA 01/2018 - 02/2009
2	Lipoprotein(a)IBA 01/2022 - 04/2009
2	Triglycerides (Triacylglycerol)IBA 01/2018 - 03/2015
2	HDL CholesterolIBA 01/2018 - 03/2015
2	Biomarkers (Surrogate Marker)IBA 12/2017 - 01/2015
2	Ferritins (Ferritin)IBA 03/2017 - 01/2015
2	IronIBA 03/2017 - 01/2015
2	Transferrin (beta 2 Transferrin)IBA 03/2017 - 01/2015
2	DNA (Deoxyribonucleic Acid)IBA 08/2009 - 04/2009
1	citrate (pro-3S)-lyaseIBA 07/2022
1	Adenosine Triphosphate (ATP)IBA 07/2022
1	MineralsIBA 01/2022
1	CreatinineIBA 01/2022
1	Tolvaptan FDA Link 01/2021
1	Recombinant ProteinsIBA 01/2021
1	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 01/2021
1	Angiotensin Receptor AntagonistsIBA 01/2021
1	TRPP Cation ChannelsIBA 01/2021
1	Cystic Fibrosis Transmembrane Conductance Regulator (Protein, CFTR)IBA 11/2019
1	Epidermal Growth Factor (EGF)IBA 11/2019
1	tetrachloroisophthalonitrile (Bravo)IBA 10/2018
1	LDL Lipoproteins (beta Lipoproteins)IBA 01/2018
1	HDL LipoproteinsIBA 01/2018
1	LDL CholesterolIBA 01/2018
1	ApoferritinsIBA 03/2017
1	Alcohol Dehydrogenase (Alcohol Dehydrogenase (NAD+))IBA 07/2014
1	SecretagoguesIBA 01/2013
1	AdiponectinIBA 01/2013
1	chondroitin synthaseIBA 12/2010
1	Bone Morphogenetic Proteins (Bone Morphogenetic Protein)IBA 12/2010
1	Plasminogen Activators (Plasminogen Activator)IBA 09/2010
1	Plasminogen Activator Inhibitor 1IBA 09/2010
1	OligonucleotidesIBA 08/2009
1	Apolipoproteins AIBA 04/2009

Therapy/Procedure

3	Precision Medicine 01/2021 - 12/2017
3	Therapeutics 01/2019 - 12/2017
1	Renal Replacement Therapy (Therapies, Renal Replacement) 12/2017
1	Coronary Artery Bypass (Coronary Artery Bypass Surgery) 07/2012